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Abstract for Gastroenterology brief report  
 
Abstract:  Interleukin 6 (IL6) is an inflammatory cytokine; signaling via its receptor (IL6R) 
is believed to contribute to development of inflammatory bowel diseases (IBD). The single 
nucleotide polymorphism rs2228145 in IL6R associates with increased levels of soluble IL6R 
(s-IL6R), as well as reduced IL6R signaling and risk of inflammatory disorders; its effects are 
similar to those of a therapeutic monoclonal antibody that blocks IL6R signaling. We used 
the effect of rs2228145 on s-IL6R level as an indirect marker to investigate whether reduced 
IL6R signaling associates with risk of ulcerative colitis (UC) or Crohn’s disease (CD). In a 
genome-wide meta-analysis of 20,550 patients with CD, 17647 patients with UC, and more 
than 40,000 individuals without IBD (controls), we found that rs2228145 (scaled to a 2-fold 
increase in s-IL6R) was associated with reduced risk of CD (odds ratio, 0.876; 95% CI, 
0.822–0.933; P=.00003) or UC (odds ratio, 0.932; 95% CI, 0.875–0.996; P=.036). These 
findings indicate that therapeutics designed to block IL6R signaling might be effective in 
treatment of IBD. 
 
KEY WORDS: SNP, genetics, Mendelian randomization, drug target validation 
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Brief report  
 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases 
affecting the gastrointestinal tract. Effective novel therapeutics remain a priority for 
these disabling conditions.  
 
Interleukin-6 (IL6) is a pro-inflammatory cytokine that can exert its biological effect 
via two mechanisms: classical signaling through its membrane-bound IL6 receptor 
(IL6R), and trans-signaling, by binding to a soluble form of IL6R (s-IL6R) and 
subsequently to the membrane-bound transducer glycoprotein 130 (gp130)1. 
Whether IL6R is an attractive drug target for the management of both UC and CD is 
unknown. 
 
Mendelian randomization (MR) can provide information on causality between an 
exposure and disease and has been successfully adopted for drug target validation2. 
This method relies on a simple principle; if a modifiable exposure (e.g. a biomarker, 
a complex trait, or an environmental risk factor such as alcohol intake) is causal for a 
disease, then the genetic variants associated with (or that mirror the biological 
effects of) that exposure will also be associated with disease risk (Figure 1). The 
causal inference is possible due to the fundamental nature of the genome; variants 
are randomly allocated at meiosis, balancing confounders, and reverse causation, 
another important source of bias in observational studies, is not possible since the 
sequence of the germline is generally not modifiable by disease. MR can therefore 
be considered in many ways analogous to a randomized controlled trial (RCT) 
(Figure 2).  
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The IL6R SNP rs2228145 leads to increased proteolysis of its product and a 
reduction in classical signaling and has similar directional effects to an existing anti-
IL6R monoclonal antibody, tocilizumab (licensed for the treatment of rheumatoid 
arthritis); these include accumulation of circulating IL6 and s-IL6R levels, most likely 
due to reduced clearance of IL6 via its receptor in the liver and termination of 
negative feedback mechanisms, as well as a reduction in downstream inflammatory 
biomarkers such as c-reactive protein (CRP), platelets and fibrinogen3. Despite 
important differences between tocilizumab and rs2228145 (the former inhibits both 
IL6R and s-IL6R, whereas the latter induces proteolysis specific to IL6R), the above 
similarities make rs2228145 an attractive genetic instrument for drug target 
validation of IL6R inhibition (Figure 2)4. Previous MR studies have demonstrated 
protective associations between rs2228145 and inflammatory conditions including 
coronary heart disease and rheumatoid arthritis3.  
 
We aimed to evaluate and quantify the effect of IL6R signaling on the risk of 
developing UC and CD using a 2-sample MR design (see Supplementary Material). 
We used the effect of rs2228145 on circulating levels of s-IL6R (and IL6, sensitivity 
analysis, see Supplementary Material) as an indirect marker for our exposure, 
reduced membrane bound IL6R and classical IL6R signaling, as described 
elsewhere (Figure 1)2,5. 
 
The SNP (rs2228145) - biomarker (s-IL6R, IL6) associations estimated in 1650 
individuals were used as genetic instruments; rs2228145 elevates serum s-IL6R 
levels by 34% (IL6 by 15%)4.  SNP - inflammatory bowel disease (IBD) associations 
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were extracted from the largest IBD Genetics Consortium meta-analysis to date6. 
The ratio MR method was used to obtain individual exposure estimates by dividing 
the SNP - outcome by the SNP - biomarker effect estimates.   
 
In a combined total of 20550 patients with CD (41642 controls) and 17647 patients 
with UC (47179 controls), rs2228145 was associated with decreased odds of CD 
(OR 0.948, 95% CI, 0.925-0.972, p = .00003) and UC (OR 0.973, 95% CI, 0.948-
0.998, p = .038) per effect allele.  When applying the ratio MR method to quantify the 
association between the indirect marker (s-IL6R) and the outcome, a two-fold 
genetic elevation of s-IL6R was associated with decreased odds of CD (OR 0.876, 
95% CI, 0.822-0.933, p = .00003) and UC (OR 0.932, 95% CI, 0.875-0.996, p = 
.036) (see Supplementary material). As a point of reference, tocilizumab increases s-
IL6R levels by approximately ten-fold2.  
 
About 90% of drugs that enter clinical development fail; genetic evidence for a 
therapeutic target doubles the clinical success rate of such drugs7. Our findings are 
consistent with 2 RCTs of antibodies targeting IL6 signaling for the treatment of CD; 
a small Phase I study of tocilizumab suggested higher clinical response rates in CD 
than the placebo group8. Additionally, a recent RCT (ANDANTE) of an anti-IL6 
antibody (PF-04236921) yielded higher clinical response and remission rates in 
patients with refractory CD versus placebo9. Rare cases of gastrointestinal 
perforation however in patients treated with both of the above antibodies remain a 
concern, since IL6 signaling may also contribute to epithelial repair of the intestinal 
mucosa10. Avoiding use in at risk individuals including patients with diverticulitis and 
active fistulae should still be advocated.  
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In the MR paradigm, genetic associations are generally free from confounding; 
previous studies have demonstrated no association between rs2228145 and age, 
birth weight and education11. Another concern for potential bias occurs when 
variants influence biomarkers on distinct causal pathways (horizontal pleiotropy). 
Genetic instruments however designed to model a protein (compared to more distal 
exposures such as complex traits) are protected from such pleiotropy12. IL6R affects 
multiple downstream biomarkers on the same causal pathway, in a similar manner to 
pharmacological blockade, a (vertical) form of pleiotropy that does not lead to bias 
(Figure 2).  
 
Interpretation of our results requires caution. A reduction in the risk of developing 
IBD does not necessarily translate to a reduction in disease progression, since 
genetic contributions to prognosis may differ to those of susceptibility13. An incorrect 
conclusion would be that “increased s-IL6R reduces the risk of developing IBD”; s-
IL6R was used as an indirect marker for reduced membrane-bound IL6R and 
subsequent classical signaling. Results should be interpreted as “a genetic reduction 
of IL6R and its classical signaling, sufficient to double s-IL6R reduces the risk of 
developing IBD”2.  
 
Our study suggests that a reduction in IL6R and subsequent classical signaling 
reduces IBD risk. One possible consequence is an increase in s-IL6R/IL6 complexes 
and subsequent trans-signaling via membrane-bound gp130. However, even if this 
occurs, it does not fully compensate for the impaired classical signaling, as 
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evidenced by the net reduction in downstream biomarkers such as CRP, platelets 
and fibrinogen. Alternatively, it has been proposed that the increase in s-IL6R may 
actually further reduce trans-signaling by enhancing the buffering potential of the 
abundant soluble glycoprotein 130 (s-gp130)14. Further work is required to determine 
the effect of rs2228145 on IL6 trans-signaling and whether trans-signaling is in itself 
a potential therapeutic target in IBD.   
 
On the basis of genetic evidence in humans, IL6R signaling seems to have a causal 
role in the development of both CD and UC; Suitably powered RCTs of new and 
existing therapeutics targeting this complex pathway are required in both conditions, 
alongside ongoing focus on the pathophysiology underlying rare complications such 
as gastrointestinal perforations. 
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Figure 1. The MR model using a variant that disrupts normal function of the 
exposure (IL6R classical signaling), indirectly measured through increased levels of 
s-IL6R and IL6. The three principles of MR analysis are: a genetic instrument is 
robustly associated with the exposure (assumption 1, continuous arrow) but not with 
confounders (assumption 2, dotted arrow). The genetic variant is associated with the 
disease only through its effects on the exposure (assumption 3, dotted arrow).  
 
Figure 2. Schematic demonstrating how MR can be considered a natural analogue 
of the classical randomized controlled trial (corresponding RCT steps in brackets). 
IL6R SNP rs2228145 has similar directional biomarker effects with tocilizumab.  
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Supplementary Materials and Methods 
 
Mendelian Randomization  
 
Mendelian randomization (MR) requires that the genetic instrument is associated 
with a modifiable exposure of interest, and any association between the instrument 
and the outcome is mediated by the exposure through its downstream effects. MR 
assesses the causal effect of an exposure (in this report, we use increased soluble 
IL-6 receptor levels (s-IL6R) as an indirect measure for our exposure, reduced IL6R 
and subsequent impaired IL-6 receptor (IL6R) signaling, as per previous studies1,2) 
on an outcome (e.g. inflammatory bowel disease (IBD)) by grouping individuals in 
the population according to the possession of the genetic variants that modify an 
exposure of interest; genetic variants should be free from conventional confounding 
since they are “assigned” randomly at meiosis; reverse causality bias is impossible 
since the germline genome is generally non-modifiable by disease. MR can be 
thought of as analogous to a randomized controlled trial (RCT) that uses genetic 
variation as the method of randomization; the key difference is that MR can be 
performed at any time using routine genotype data, without the exposure of patients 
to the drug.  Advances on MR methodology have allowed for the measurement of 
genetic effects on exposure and outcomes in independent samples (2 sample MR); 
this has enabled the use of publically available results from very large genome wide 
association studies (GWAS) for both risk factor “exposures” and disease “outcomes” 
to evaluate causal relationships3. By using genetic variants that effect known drug 
targets and have quantifiable effects, MR offers a relatively unbiased approach for 
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the prediction of both intended (e.g. RCT endpoints) and unintended (e.g. drug 
repurposing opportunities, adverse events) drug effects. 
 
Genetic datasets used 
 
SNP-Crohn’s disease (CD), SNP-ulcerative colitis (UC), ln (odds ratio) and standard 
errors were downloaded from the most recent IBD Genetics Consortium meta-
analysis (https://www.ibdgenetics.org/downloads.html). 
 
Study outcome 
 
The primary outcome was the risk of developing a) CD b) UC per two-fold elevation 
in circulating s-IL6R as an indirect measure for our exposure (genetically impaired 
IL6R signaling).  
 
Statistical analysis 
 
The SNP- IBD associations were extracted as described above and presented per 
effect allele. The SNP - s-IL6R were estimated in 1,650 individuals included in a 
large collaborative MR study4. These estimates were presented in percentage 
differences, which were converted to ln- transformed units.  
 
Single-nucleotide polymorphism (SNP) - s-IL6R and IL6 associations were collected 
in ln-transformed units from previous publications (Table 1).  
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The ratio MR method was used. This method was used to obtain individual SNP 
estimates by dividing the SNP – outcome by the SNP – biomarker effect estimates. 
Analysis were performed using R package MR-Base, version 3.2.4 (http://www.r-
project.org).5 
 
Odds ratio (OR) estimates of UC and CD were transformed (for ease of 
interpretation). Results were presented per two - fold increase in circulating s-IL6R 
and IL6 levels: 
 
(√
 )2 
 
Where OR is the odds ratio estimate per 1-ln increment in biomarker levels and e is 
the base of the natural logarithm. 
 
Sensitivity Analysis 
 
When applying the ratio MR method to model the association between the indirect 
marker IL6 and the outcome, a two-fold genetic elevation of IL6 was associated with 
decreased odds of CD (OR 0.75, 95% CI, 0.81-0.94, p = .00003) and UC (OR 0.861, 
95% CI, 0.71-1, p = .038). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Table  1. The SNP- s-IL6R and SNP- IL6 associations (per Effect Allele) generated 
from a previous study were used as genetic instruments in this report. SNP: single 
nucleotide polymorphism. CRP: C-reactive protein. IL6R: Interleukin-6 receptor. EA: 
effect allele. OA: other allele. OR: odds ratio. 
 
Gene SNP EA OA Biomarker ln(levels) SE 
IL6R rs2228145 C A s-IL6R 0.2949 0.0148 
IL6 rs2228145 C A IL6 0.1362 0.0176 
 
Table 2. SNP-Crohn’s disease and SNP-ulcerative colitis (per Effect Allele) 
associations downloaded from available GWAS summary statistics, presented here 
after data harmonization. SNP: single nucleotide polymorphism. CD: Crohn’s 
disease. UC: Ulcerative colitis.  CRP: C-reactive protein. IL6R: Interleukin-6 receptor. 
OR: odds ratio. SE: Standard error. EA: effect allele. OA: other allele. 
 
Study Disease SNP EA OA ln(levels) SE 
Liu6 CD rs2228145 C A -0.0530323 0.0126631 
Liu6 UC rs2228145 C A -0.0276154 0.0131298 
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